Shares of Viridian Therapeutics, Inc. (VRDN), have advanced 29% since my last update in December 2024 but are still down 35% since my first published article on Seeking Alpha. The last few years were ...
- Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track - - Topline phase 3 results for ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results